83 active trials 40 recruiting 29 Phase 3 58 sponsors 10 changes in 30 days
| Early Phase 1 | 2 | |
| Phase 1 | 7 | |
| Phase 1/2 | 7 | |
| Phase 2 | 28 | |
| Phase 2/3 | 3 | |
| Phase 3 | 26 | |
| Phase 4 | 2 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease… | The First Affiliated Hospital of Soochow University | Recruiting | 2025-06-12 |
| NCT07709884 | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly… | The First Affiliated Hospital of Soochow University | Not Yet Recruiting | 2026-07-17 |
| Phase 3 | ||||
| NCT05623020 | A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and… | Pfizer | Recruiting | 2026-08-24 |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple… | ECOG-ACRIN Cancer Research Group | Recruiting | 2026-08-19 |
| NCT07285239 | Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for… | PrECOG, LLC. | Recruiting | 2026-08-17 |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | AstraZeneca | Recruiting | 2026-08-14 |
| NCT05552222 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and… | Janssen Research & Development, LLC | Recruiting | 2026-07-06 |
| NCT05558319 | NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs… | PETHEMA Foundation | Recruiting | 2026-06-25 |
| NCT05561387 | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a… | SWOG Cancer Research Network | Recruiting | 2026-06-10 |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone… | European Myeloma Network B.V. | Recruiting | 2026-06-04 |
| NCT06679101 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and… | GlaxoSmithKline | Recruiting | 2026-04-22 |
| NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib… | Sinocelltech Ltd. | Recruiting | 2026-01-29 |
| NCT00602641 | Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly… | National Cancer Institute (NCI) | Active, Not Recruiting | 2026-08-27 |
| NCT06216158 | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly… | University of Heidelberg Medical Center | Active, Not Recruiting | 2026-08-17 |
| NCT07735637 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared… | AstraZeneca | Not Yet Recruiting | 2026-07-30 |
| NCT04483739 | Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem… | European Myeloma Network B.V. | Active, Not Recruiting | 2026-07-16 |
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a… | Janssen Research & Development, LLC | Active, Not Recruiting | 2026-07-06 |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy… | Bristol-Myers Squibb | Active, Not Recruiting | 2026-07-02 |
| NCT07624513 | Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… | Dana-Farber Cancer Institute | Not Yet Recruiting | 2026-06-03 |
| NCT03319667 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib… | Sanofi | Active, Not Recruiting | 2026-05-04 |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple… | Pfizer | Active, Not Recruiting | 2026-04-16 |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by… | Stichting European Myeloma Network | Active, Not Recruiting | 2026-03-17 |
| NCT06045806 | A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide… | Celgene | Active, Not Recruiting | 2026-03-05 |
| NCT03729804 | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and… | University of Chicago | Active, Not Recruiting | 2026-03-04 |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With… | ECOG-ACRIN Cancer Research Group | Active, Not Recruiting | 2025-09-08 |
The First Affiliated Hospital of Soochow University (4) · Dana-Farber Cancer Institute (3) · European Myeloma Network B.V. (3) · Janssen Research & Development, LLC (3) · National Cancer Institute (NCI) (3) · PETHEMA Foundation (3) · AstraZeneca (2) · Bristol-Myers Squibb (2) · Celgene (2) · ECOG-ACRIN Cancer Research Group (2)